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Abstract
Insulin action and obesity are both correlated with the density of muscle capillary supply in humans. Since
the altered muscle anatomy in the obese might affect interstitial insulin concentrations and reduce insulin
action, we have cannulated peripheral lymphatic vessels in lean and obese males, and compared
peripheral lymph insulin concentrations with whole body glucose uptake during a euglycemic,
hyperinsulinemic clamp. Lymph insulin concentrations in the lower limb averaged only 34% of arterial
insulin concentrations during 150 min of insulin infusion. Obese subjects had the highest arterial (P <
0.0001) and lymph insulin (P < 0.005) concentrations, but the lowest glucose uptake rates (P < 0.002). In
contrast to the initial steep rise then plateau of arterial insulins, both lymph insulin and whole body
glucose uptake rates rose slowly and did not consistently reach a plateau. In each individual, the glucose
uptake closely correlated with peripheral lymphatic insulin concentrations (mean r2 - 0.95). The coupling
between glucose uptake and lymph insulin (glucose uptake/pmol insulin) was much steeper in lean
subjects than in the obese (P < 0.0001). These results indicate that even if insulin diffusion into tissues is
rate limiting for insulin action, a tissue defect rather than an insulin diffusion defect causes insulin
resistance in obese subjects.
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Interstitial Insulin Concentrations Determine Glucose Uptake Rates
but Not Insulin Resistance in Lean and Obese Men
Charles Castillo, Clifton Bogardus, Richard Bergman,* Pam Thuillez, and Stephen Lillioja
Clinical Diabetes and Nutrition Section, National Institutes of Diabetes, and Digestive and Kidney Diseases, National Institutes of
Health, Phoenix, Arizona 85016; and *Department ofPhysiology, University of Southern California, Los Angeles, California 90033

Abstract
Insulin action and obesity are both correlated with the density
of muscle capillary supply in humans. Since the altered muscle
anatomy in the obese might affect interstitial insulin concentrations and reduce insulin action, we have cannulated peripheral
lymphatic vessels in lean and obese males, and compared peripheral lymph insulin concentrations with whole body glucose
uptake during a euglycemic, hyperinsulinemic clamp. Lymph
insulin concentrations in the lower limb averaged only 34% of
arterial insulin concentrations during 150 min of insulin infusion. Obese subjects had the highest arterial (P c 0.0001 ) and
lymph insulin (P < 0.005) concentrations, but the lowest glucose uptake rates (P < 0.002). In contrast to the initial steep
rise then plateau of arterial insulins, both lymph insulin and
whole body glucose uptake rates rose slowly and did not consistently reach a plateau. In each individual, the glucose uptake
closely correlated with peripheral lymphatic insulin concentrations (mean r2 = 0.95). The coupling between glucose uptake
and lymph insulin (glucose uptake/pmol insulin) was much
steeper in lean subjects than in the obese (P < 0.0001). These
results indicate that even if insulin diffusion into tissues is rate
limiting for insulin action, a tissue defect rather than an insulin
diffusion defect causes insulin resistance in obese subjects. (J.
Clin. Invest. 1994. 93:10-16.) Key words: lymph* lymphatic
cannulation * euglycemic clamp * skeletal muscle * arterio-venous difference

Introduction
The reason some obese subjects develop insulin resistance is
not known but several mechanisms have been proposed. An
elevated supply of free fatty acids could reduce glucose oxidation ( 1, 2), leading to glycogen accumulation and downregulation of glycogen synthase (3), and failure to dispose of glucose
in response to insulin. The mechanism is applicable, but the
degree to which defects in glucose storage may develop chronically, and the fact that obesity seems to affect insulin action at
supraphysiological insulin concentrations (4, 5) when free
fatty acids are markedly suppressed, suggest that other mechanisms may also apply. Altered phospholipid content of cell
membranes appears to be related to insulin resistance (6, 7),
This material has appeared in abstract form (1991. Diabetes. 40
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and it is possible that overfeeding in the development of obesity
might produce effects by the way lipids are incorporated in cell
membranes. An increased supply of amylin cosecreted with
insulin during overfeeding and weight gain might create an
impairment of insulin action (8, 9). Finally, a reduced density
of capillary supply and enlarged skeletal muscle fibers are related to obesity and insulin resistance (4). Previous studies
have indicated that insulin concentrations are reduced in
lymph compared with concentrations in arterial blood ( 1012), and we have postulated that physical changes in skeletal
muscle might alter insulin action by affecting the equilibration
of insulin in the tissues (4, 13). Studies in dogs by Yang et al.
( 14) and insulin kinetics studies in humans ( 15-18) have appeared to support this hypothesis.
The current studies show that insulin concentrations are
indeed reduced in lymph and presumably in the rest of the
interstitial space. However, the coupling between glucose uptake and insulin concentration is lower in the most obese, indicating that while capillary transport of insulin may be rate limiting for insulin action in any one individual ( 14), a cellular
defect in insulin action and not a defect in insulin penetration
to the interstitial space is the cause of insulin resistance in obese
subjects.

Methods
Subjects. 13 healthy Caucasian males representing a wide range ofobesity were studied. The results of lower limb lymph flow measurements
in these subjects have been published in detail already ( 19). Subject
G.F. from this prior publication is not used in the current analysis
because of missing data. All subjects were nondiabetic as determined
by a 75-g oral glucose tolerance test (20). Mean body mass index was
30.4 kg/iM2 (ranging from 20.8 to 57.3 kg/iM2). Mean percent body fat
from underwater weighing (21, 22) was 22.3% (ranging from 6.1 to
46.8%; see Fig. 3). Mean age was 30.6 yr (ranging from 21.2 to 36.6
yr). Metabolic size (ms)' is fat-free mass + 20 kg (c.f. reference 13).
Lymphatic cannulation. A recent publication has been devoted to a
description of the lymphatic cannulation method ( 19). In brief, a fine
catheter was prepared by heating the tip of a 5-in, 20-gauge polyurethane catheter (Arrow International, Reading, PA) and stretching it to
a fine taper. The tip, at a diameter of 0.35-0.45 mm, was then compatible with the diameter of lymphatic vessels. Lymphatic vessels were
detected in the epifascial subcutaneous tissue of the leg 15 cm proximal
to the medial malleolus, between the medial border of the tibia and the
saphenous vein, after an injection ofisosulphan blue into the pedal web
spaces. The lymph vessels were cannulated by the Seldinger technique
using 4-0 nylon and a 25-gauge needle. Lymph was collected in a
vented EDTA vacutainer tube, and the weight oftubes before and after
lymph collection enabled the lymph volume to be calculated. Lymph
was collected at 1 5-min intervals during the metabolic studies, and flow
rates ranged from 0.34 to 4.96 ml/h. In each subject the lymph vessels
were cannulated the day before the metabolic study and a collecting
tube was in place for 24 h. During the metabolic procedure (see
-

1. Abbreviations used in this paper: A-V, arterio-venous; MS, metabolic size.

below), the foot of the cannulated leg was placed in a warming box at

420C with a venapulse VP-50 pneumatic compressor cuff (ACI Medical, Sun Valley, CA) applied to the forefoot. The latter gave pressure
pulses at 3-s intervals to increase intrinsic lymphatic contractions.
These measures were to increase lymph flow, without increasing metabolic demands (23, 24). The lymph collected in these studies is presumably from subcutaneous tissues of the ankle and forefoot and not from
skeletal muscle.
Metabolic studies: euglycemic clamp. Glucose uptake was measured during a euglycemic clamp as previously described (4, 25), except that no priming dose of insulin was given. The following cannulation schedule was used: a central venous line for glucose, 3- [3H Iglucose, and insulin infusions in the left antecubital vein; an arterial
catheter in the right radial artery; a lymph cannula in the left lower
extremity; a venous catheter in the right femoral vein with a thigh-high
TED antiembolism stocking (Kendall Co., Manifield, MA) on that
limb.
A primed continuous infusion of 3- [3H ] glucose was commenced at
- 120 min and continued for the duration of the test, which lasted 240
min from time 0. At 0 min an infusion of purified pork insulin (Nordisk, Bethesda, MD) was commenced at an infusion rate of 290 pmol/
m2 body surface area per min and continued for 150 min and then
abruptly stopped. The patient was observed for a further 90 min. At
0 min an infusion of 20% glucose was commenced and the rate ofits
infusion varied to maintain euglycemia. The 20% dextrose contained
trace amounts of 3- [3H ] glucose according to the methods described by
Finegood et al. and Bergman et al. (26, 27). The 20% glucose infusion
was continued as needed for the 240 min.
The arterial line was sampled for glucose, basally and at 5-min
intervals to 240 min, and was sampled for [3H]glucose and insulin at
10-min intervals from 0 to 240 min. The femoral venous line was
sampled basally and at 10-min intervals from 0 to 240 min for glucose
and insulin. Lymph samples were collected at 15-min intervals for
glucose and insulin.
Insulin concentrations in plasma and lymph were measured by a
coated tube method using a radioassay analyzer (Concept 4; I.C.N.,
Horsham, PA). 3- [3H ]Glucose was measured as previously described
by others (28) using perchloric acid to precipitate proteins.
Hot glucose infusion. The hot glucose infusion method was used in
this study to minimize errors due to the weakness of the single compartment model (26, 27, 29). Within experimental error the assumptions of the methods appear to have been met; hence, by paired t test
mean specific activity did not change from basal to insulin on, insulin
on to insulin off, or basal to insulin offi Also, by paired t test there was
no significant difference between rate of dissapearance (Rd) from 3[3H] or exogenous infusion examining the 90-210-min time period
when the liver should be suppressed. This was also true if the two most
insulin-resistant or four most insulin-resistant subjects were not included. The rate of glucose disappearance at any particular 10-min
interval was calculated as the maximum of either Rd from 3-[3H]glucose analysis or the exogenous glucose infusion. This calculation has
the advantage of providing a glucose uptake rate when there was incomplete hepatic suppression, such as in the first and last minutes of
the studies. Furthermore, since 3H and exogenous methods gave similar results, using both helps minimize random experimental error.
Statistical analyses. Data were smoothed before analysis using running means with care not to smooth over sharp transitions (such as
when insulin was stopped at 150 min). Data were analyzed using the
programs of the Statistical Analysis System Institute (Cary, NC) including RSQUARE, CORR, and MEANS procedures. Lymph samples
were collected at 15-min intervals, and arterial insulin at 1 0-min intervals. Linear interpolations were used after smoothing to provide 5-min
intervals and allow correlation of lymph insulin and glucose uptake.
The regression of lymph insulin and glucose uptake was performed by
repeatedly analyzing the relationship after lymph insulin values are
moved to the left in Fig. I (but using one individual at a time) by 5-min
increments. The best r2 was taken as the best fit. The two most obese
individuals had essentially no insulin action, and these regression pro-

cedures were not meaningful (see Fig. 3 and legend). It was felt important to analyze the whole 240 min in one model to assess this lag, but
the change in regression slope after 150 min (see Fig. 2, inset) meant
that a more complex regression model was needed. The regression
model had to allow for two straight lines that intercepted at a sharp
point at a specific time. The form of the regression model was: U = flo
+ fl, L + f2Z(L - C), where U is glucose uptake, L is lymph insulin, Z
is 0 below 150 min and 1 above that time point, and C is the value ofL
at 150 min. This regression produces straight lines that intercept at C,
but C is not necessarily the apogee of glucose uptake or lymph insulin.
Such an analysis is described as piecewise or spline regression (30). For
the regression analysis involving time the model used was: U = f4
+ f35L + 36T, where U is glucose uptake, L is lymph insulin, and T is
time point at which glucose uptake was measured. The results showed
that the coefficient of the time variable was not significant in those
subjects where the slope did not change at 150 min.

Results
Arterial insulin concentrations rose rapidly and reached a
plateau, and then rapidly declined when the insulin infusion
was stopped (Fig. 1). The insulin concentrations in the most
obese subjects stabilized higher (P < 0.0001 ). By contrast, the
lymph insulin concentration rose slowly after an initial delay
and did not clearly reach a plateau. Again, the most obese had
the highest values (P < 0.005). The mean lymph insulin averaged only 34% of the mean arterial insulins (range, 18-60%)
during the 2.5 h of insulin infusion, even taking account of the
delays involved in lymph reaching the sampling site (see below). The ratio of lymph to arterial insulin did not vary with
obesity (P = 0.6).
In Fig. 1, bottom, the rate of glucose uptake over time can
be compared with the simultaneous insulin concentrations.
The most obese two individuals had essentially no insulin action. The glucose uptake time course was very similar to that of
the lymph insulin and markedly different from the time course
of the arterial insulin concentration. This was true even though
the lymph sampled is from the subcutaneous tissues of the
medial ankle and forefoot. This suggests, not surprisingly, that
insulin concentrations in lymph are more similar to those in
the compartment from which insulin acts than are arterial insulin concentrations.
The correlation of insulin concentrations and glucose uptake values were assessed in each individual excluding the two
individuals with essentially no insulin action. A regression of
arterial insulin and glucose uptake was, as expected considering Fig. 1, rather poor (mean r2 = 0.15; range, 0.0-0.37). The
regression of lymph insulin and glucose uptake was better
(mean r2, 0.48; range, 0.09-0.74). However, the lymph insulin
appeared to be delayed relative to glucose uptake (Fig. 1 ), and
it was also apparent that the relationship changed in some individuals after the insulin infusion was stopped (Fig. 2). By introducing a lag time of 20 min between lymph insulin sampling, and allowing the relationship between glucose uptake
and lymph insulin to change at 150 min, the regression of these
two variables improved markedly (mean r2 = 0.91; range,
0.78-0.97). Finally, if each individual was allowed their own
lag time (mean, 22 min; range, 0-50 min), the relationship of
lymph insulin and glucose uptake gave a mean r2 of 0.95
(range, 0.91-0.995); i.e., 95% of the variance in glucose uptake
in an individual is explained by the variance in lymph insulin.
These data indicate that insulin action in peripheral tissues is
Interstitial Insulin Concentrations and Insulin Action
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Figure 1. Arterial and lymphatic insulin concentrations during ( 150
mmn) and after (90 mmn) the infusion of insulin into an antecubital
vein at a rate of 290 pmol/m2 body surface area per mmn in 13 healthy
nondiabetic Caucasian males. For convenience of presentation, the
data are grouped by degree of obesity (percent body fat from densitometry [l0]: A,.c 12%; *, 13-21%;a, 22-35%; a,.236%; compare
Fig. 3, where data are presented for each individual). Dextrose (20% )
was infused to maintain euglycemia. The insulin concentrations in
arterial plasma rapidly reached steady state and were higher in the
most obese. Lymphatic insulin concentrations increased slowly and
were in some cases still approaching steady state after 150 mmn but
were also highest in the most obese. Glucose uptake showed a similar
time course to the lymphatic insulin except that the most obese
showed essentially no response, and the ranking in glucose uptake is
the reverse of the insulin concentrations. Arterial insulin and glucose
uptake were measured every 10 min, and lymph insulin every 15 mmn

during insuln infusion.

determined by a compartment with an insulin concentration
closely related to the insulin concentration in lymph.
Lymph flow rate was correlated with percent body fat (r
= 0.75, P < 0.004), but the lag time was not correlated with
either obesity (P = 0.16) or lymph flow rate (P = 0.29).
The flows averaged 1.84 mi/h or 0.46 ml/specimen, and the
12
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volume of the catheter was - 0.05 ml, so that transit time
through the catheter was on average 1.6 min, ranging from 50 s
to 5 min.
In some subjects there was a change in relationship of
lymph insulin to glucose uptake after the 1 50-min time point
when the insulin infusion was stopped (Fig. 2, inset). In 7 of 11
subjects the slope was steeper and lower after 150 min than
before, in 1 subject the slope was shallower and higher, and in 3
subjects it was not significantly different. This change in slope
was not due to a change in the glucose-specific activity. Those
three subjects without a change in slope were also the leanest,
and the subject with the increase in slope was the fifth leanest.
The most likely explanation for this change in slope is that
glucose uptake relative to insulin concentration is steadily decreasing throughout the test and this continues after the insulin
infusion ceases. In Fig. 2 each data point is in chronological
sequence. One could imagine in Fig. 2 a line that passes
through the basal data point from subject 3, for example, but is
steeper than the upslope illustrated. As time proceeds the glucose uptake at a given insulin concentration falls further and
further below this idealized line. When the lymph insulins begin to fall after stopping the insulin infusion, the glucose uptake
continues to drop below this idealized line so that now insulin
at 175 pmol/liter, for example, is even less effective than it was
60 min before. This hypothesis is confirmed by an analysis in
which the lymph curves are lagged as above, but instead of
allowing the slope to change at 150 min the regression equation
uses lymph insulin and time to predict glucose uptake (see
Methods). The mean r2 in this case was 0.94, ranging from
0.84 to 0.994 (not affected if three leanest subjects who had
neither a change in slope nor a significant time effect are not
included). The sign of the coefficient of time was the same as
on the change in slope. That is, if the slope becomes steeper
after 150 min the coefficient for time in the regression is negative (time results in a decreased effect of insulin).
This time-dependent effect is not enough to explain the low
slopes in insulin-resistant subjects. In Fig. 2 the slope without a
time-dependent effect would have been 0.6 mg/kg MS per min
higher for subject 5 at 150 min and 0.22 mg/kg MS per min
higher for subject 6 at 150 min.
There was a wide variation in the coupling of glucose uptake and lymph insulin, as shown in Fig. 2. That is, in some
individuals there is little glucose uptake change in spite of a
large change in lymph insulin, while in others a small change in
insulin results in large changes in glucose uptake. This information is summarized in Fig. 3, where the slope of the initial
glucose uptake relationship (0-1 50 min) is plotted against percent body fat. Clearly, the most obese have a lower coupling of
glucose uptake to lymph insulin. Insulin resistance is usually
assessed by the glucose uptake (in mg/ min) during some time
interval near the end of an insulin infusion. For comparison
with such data, the initial slope of the glucose uptake/lymph
insulin relationship in each individual was correlated with the
glucose uptake during 0-150 min (r = 0.88, P < 0.0001), 120150 min (r = 0.92, P < 0.0001), and during 0-240 min (r
=0.90,P<0.000I).
We have also compared the mean arterio-venous (A-V differences and mean uptake rate of glucose over 150 min of insulin infusion (Fig. 4). Both values are highly correlated (r
= 0.88, P < 0.0001 ). It can be seen that in the most insulin-resistant subjects the percent A-V difference is quite small. In
contrast the percent A-V difference is high in the more sensi-
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Figure 2. Correlation of whole body
glucose uptake with peripheral lymphatic insulin concentrations. Only
six individuals are shown to preserve
clarity. For five individuals (main
figure) only the first 150 min (insuislinAll
infusion) is shown, and the vanability in uptake/insulin coupling is

polation because arterial values were
collected at 10-min intervals and
lymph at 15-min intervals. The regression lines (-) and data points
(1-6) show the close correlation of
glucose uptake and lymphatic insulin in each individual (mean r2
= 0.95: range, 0.91-0.995). The in6 66the6 whole
set/shows
id time course
(150-mmn insulin infusion. 90-min
insulin infusion stopped) in one in-

dividual showing that after 150 min
the correlation is also close but on a
different and steeper line. In this
,
,
1 4e ,
subject in the inset, for example,
o
50
loo
150
200
250
300
350 glucose uptake = 1.15 + (0.020
LYMPH INSULIN (pmol/L)
x insulin) below 150 min; and glucose uptake = 1.15 + (0.020 X insulin) + (0.025 X [insulin - 242])
above 150 min, where the insulin at 150 min was 242 pmol/liter (r2 = 0.99). If, instead. time is used as a variable the relationship becomes
glucose uptake = 0.68 + (0.028 x insulin) - (0.012 x time), where time is in minutes from the start of the test (r2 = 0.97). This suggests that
after 90 min the glucose uptake is 1.1 mg/kg MS per min less than it would have been without a time-dependent effect. After 150 min the
glucose uptake is 1.8 mg/kg MS per min less than it might have been and after 240 minm 2.9 mg/kg MS per min less than otherwise.

tive, leaner subjects, indicating that the flow rate is most limiting for glucose diffusion in sensitive individuals. The percent
A-V difference of insulin across the leg averaged 19%, but was
not correlated with obesity (P = 0.8) or with glucose uptake (P
= 0.6).

Discussion
We have studied 13 young men of varying degrees of obesity to
assess, both within and between individuals, the relationship of
interstitial insulin concentrations and insulin action. The results show that lymph insulin concentrations are a good estimate of the concentration of insulin at the site where insulin
exerts its action on glucose uptake. The supply ofinsulin to this
compartment, however, is not the cause of any apparent insulin resistance in obese subjects. This is demonstrated by the fact
that the most obese insulin-resistant subjects had the highest
lymph insulin concentrations and these subjects also had the
lowest coupling between glucose uptake and insulin concentrations in lymph. Hence, insulin resistance in obese subjects is
not due to failure of insulin to reach its site of action but due to
factors in the tissues themselves.
A "continuous" capillary endothelium is a significant
barrier to free diffusion from blood into tissues such as skeletal
muscle, adipose tissue, and skin (31, 32). The glycocalyx, the
basement membrane, and the interstitium beyond the capillary
contribute to reduced diffusion (33-35). Hence, gradients of
insulin concentration from capillary to tissue are inevitable
when plasma insulin concentrations change. It has been known
for some time that insulin concentrations in the lymph of dogs

are lower than, and do not fluctuate as widely as, simultaneous
arterial and venous insulin concentrations ( 10-12). Hence,
available evidence indicates that penetration of insulin to its
site of action is delayed by the capillary wall in spite of transport or direct effects of insulin on macromolecular diffusion
(36, 37).
In this study we have collected lymph that probably drains
from subcutaneous tissues of the ankle and foot. It would have
been preferable to sample lymph from skeletal muscle, the
dominant site of insulin action in a study such as this (38).
Lymphatics in skeletal muscle follow arterioles and venules
and do not even accompany capillaries (39). Hence, it may be
impossible to sample the interstitial fluid bathing muscle cells
by sampling lymph. The lymph values here may, therefore, be
no different from those of lymphatics draining a muscle, especially since the capillaries of skeletal muscle, adipose tissue,
and skin are all similarly "continuous" (31, 32). It is not
known if there are insulin gradients deep within the muscle
interfiber clefts, and, therefore, it is difficult to even estimate
what insulin concentrations are engulfing a muscle cell (compare reference 13). The good correlation of lymph insulin and
whole body glucose uptake suggests the methodology must
have been appropriate, however.
Studies of insulin kinetics, the first euglycemic clamps
(15), indicated that insulin action in humans is significantly
delayed relative to changes in arterial insulin, and modeling
suggested that insulin was acting from some remote and slowly
equilibrating compartment. Ex vivo studies have also shown a
slow-onset insulin action relative to changes in arterial insulin
(40). Furthermore, glucose uptake and lymph insulin have

Interstitial Insulin Concentrations and Insulin Action

13

z
z

160.00-

z

80.00-

A *

I

AA

-J 40.000

E

w

X

'.

0

20.00-

I-.-

oLE

D)

6

)n
0
D

ob

10.00*

=

C.

0

5.00-

-J E
O_

o

2.50-

w

Obesity Groupings

0.
0

i;'

0

0

aIt

1.250

10
20
30
40
PERCENT BODY FAT (%)

50

Figure 3. The initial slope of glucose uptake/lymph insulin relationship (from Fig. 2) in all subjects vs. degree of obesity (percent body
fat) (r = -0.91, P < 0.0001 ). There is a wide variation in the coupling
between insulin and glucose uptake depending on the degree of obesity (Note one observation is hidden. The observations at that point
have values of slope 16.7 and 16.6 [mg/kg MS per min]/[nmol/liter]
and percent fat of 16.1 and 16.4, respectively). In 11 individuals the
slope was determined by optimizing the linear regression of glucose
uptake and lymph insulin for the whole 240 min by allowing for a
lag between insulin uptake and lymph insulin appearance, and by allowing the slope to change once. Two individuals (see Fig. 1) had
essentially no insulin action and this procedure could not be performed meaningfully. For those two, the regression of glucose uptake
and lymph insulin in the first 150 min, with a 20-min lag of lymph
insulin concentrations, provided the slope value that is plotted.

is that insulin acts from an even more remote compartment
that is equilibrating slowly with the lymph compartment. This
seems unlikely since the expected effect then would have been a
greater persistence of insulin action rather than a reduction.
Further studies will be needed to test this conclusion about the
waning of insulin action since no previous studies in vivo are
available to compare insulin action with insulin concentrations
in a compartment close to the site of insulin action. The contribution of this time-dependent effect to insulin resistance may
be small, however, compared with other factors reducing insulin action.
An important implication of the current studies relates to
pulsatile insulin secretion (41-44). It is apparent that rapid
fluctuations of insulin concentrations are so dampened as to be
largely absent at the site of insulin action in the periphery. This
damping of insulin fluctuations does not apply to the liver,
however. The liver capillaries are discontinuous (31 ), and it is
possible that the liver will be affected by fluctuations of insulin
differently to the periphery (43, 44, but compare reference 42).
It is possible, therefore, that sharply fluctuating insulin concentrations serve to selectively signal the liver and not the periphery.
Elegant studies by Laasko et al. and Baron et al. (45, 46)
have demonstrated a reduced activation of lower limb blood
flow in obese subjects in response to insulin. These are significant findings but still leave a critical question unanswered: Is
the reduced blood flow a cause or an effect of insulin resistance? There is a strong correlation between A-V glucose difference and whole body glucose uptake in our data (Fig. 4), and
24
-

1.2

la

-20

-

been shown to be correlated in dogs ( 1 1, 14). These and related
findings and the demonstration of a correlation between reduced capillary density in m. vastus lateralis (4) led us to postulate that reduced capillary density in the obese (4, 13) might
result in altered tissue concentrations and an "apparent" insulin resistance. The studies of Yang et al. ( 14) in dogs lent further support to this view. Unless there are large gradients of
insulin deep within the interfiber clefts in muscle that cannot
be detected in this study, the current data refute this hy-

pothesis.
Yang et al. ( 14) provided evidence that insulin penetration
into tissue was rate limiting for insulin action in dogs. The
current studies do not contradict this, but do demonstrate that
penetration of insulin into the interstitium does not distinguish
insulin-sensitive and insulin-resistance individuals, i.e., insulin
penetration into tissues may be equally rate limiting in the lean
and the obese. The large variation in the coupling of glucose
uptake with lymph insulin and the correlation of this coupling
with obesity indicates that tissue factors determine insulin resistance in obese humans.
An unexpected finding in this study was the change in slope
of the relationship of glucose uptake and lymph insulin after
the insulin infusion was stopped. The most likely explanation
for this is a steady decline in insulin action from the very start
of the infusion, and the time-dependent decrease in insulin
effect could be demonstrated directly in a regression of glucose
uptake with lymph insulin and time. An alternate explanation
14
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Figure 4. Mean arteriovenous glucose difference (mmol/liter) and
mean glucose uptake rate over 150 min of insulin infusion (r = 0.88,
P < 0.0001 ) (symbols defined in Fig. 3). x-axis intercept (zero lower
limb glucose uptake) = 1.69 mg/kg MS per min. Since studies were
performed at - 100 mg/dl (99.2 mg/dl; range, 96-107 mg/dl), the
A-V difference (in mg/dl; right-hand scale) is approximately equal to
a percent A-V difference. Low A-V differences indicate that substrate
uptake is limited by the rate of diffusion ("diffusion limitation") (47,
48). When much of the substrate in the artery disappears before
reaching the vein then the uptake of the substrate is predominantly
limited by the amount presented to the tissue by blood flow ("flow
limitation") (47, 48). Increased flow rates alone across the limb are
only effective if extraction (percent AV difference) is high; therefore,
insulin-sensitive subjects will benefit the most from changes in blood
flow alone. This might indicate that low blood flow responses to insulin infusions (45, 46) are themselves an effect of insulin resistance.

those with little whole body glucose uptake have small A-V
differences. With a constant arterial blood glucose the A-V difference of glucose across the lower limb in an individual depends on the glucose diffusion gradient from the interior of
capillaries to cells (due to insulin), and the rate at which glucose-rich blood is supplied to the limb. If blood flow is low and
glucose consumption is high, then a large A-V difference is
created ("flow limited" uptake [47, 48]). If, in contrast, blood
flow is high and glucose consumption is low, further increases
in blood flow are only wasteful since apparently little glucose is
needed ("diffusion limited" uptake [47, 48]). In this situation
an increase in blood flow alone merely results in a further drop
in the A-V difference, not an increase in tissue glucose uptake.
It can be seen from Fig. 4 that only the lean, insulin-sensitive
subjects have a sufficiently large A-V difference such that increases in blood flow alone will increase glucose uptake significantly.
In those subjects with insulin resistance and a low A-V difference of glucose an increase in the number of capillaries perfused should result in some improvement of glucose uptake by
increasing tissue insulinization and by increasing the capillary
surface area for glucose diffusion (49). There was, however, no
relationship between the percent A-V difference in insulin
across the lower limb and obesity. This indicates that insulin
diffusion in the lower limb in the obese is not reduced relative
to lean subjects, consistent with the lymph studies, and an increase in blood flow in obese individuals might not be any
more beneficial to them than to the lean subjects in respect to
tissue insulinization. We conclude from the facts that flow is
more limiting in the lean subjects, that interstitial insulin is not
reduced in the most obese, and that cellular insulin resistance is
implied by the low coupling between glucose and lymph insulins that it is likely the low limb blood flows in obese individuals are not a cause of their insulin resistance but rather an
effect of insulin resistance that prevents the wasteful direction
of cardiac output to tissues where blood flow is already supplying glucose well.
Glucose uptake did not necessarily reach plateaus in this
study, therefore, the half-times of activation are difficult to assess, likewise, we cannot assess half-times of activation oftissue
insulin concentrations and especially so since the appearance
of lymph at the skin appeared to lag behind its action in the
tissues. Therefore, we are not able to address the issues of
whether in obese subjects the delay in insulin activation of
glucose found by Prager et al. ( 16) and Doeden and Rizza ( 17)
might be due to delay in insulin penetration into tissues, or due
to factors at, or in, the muscle cells.
The correlation of glucose uptake and capillary density (4)
may require other explanations than those previously proposed
(4, 13). The answer may lie in the biochemical properties that
accompany differences in capillary density and muscle fiber
type. Human skeletal muscle is composed of mixed fiber types.
Fiber types are determined by the histological staining properties of myosin ATPases. These staining characteristics are determined by myosin biochemical structure and are associated
with different reaction speeds, which determine the cell twitch
characteristics (50-52). These histological properties also reflect the coordinated cellular expression of multiple other enzymes (5 3, 54). A greater density of capillary supply is found in
type I muscle fibers (55, 56, compare reference 57), which are
oxidative, slow twitch (0-52), and more insulin sensitive (58,

59). Type IIB fibers are at the opposite physiological extreme
of type I fibers. The real correlation of capillary supply appears
to be with muscle cell mitochondrial content (55), and the
correlation of capillary density with fiber type is due to the
association of fiber type with mitochondrial content. It is possible, therefore, that glucose uptake is associated with muscle cell
biochemical properties, of which myofibrillar ATPase and capillary density are only markers.
In conclusion, insulin concentration changes in arterial
blood in man are followed by changes in lymphatic insulin
concentrations that are both delayed and reduced. It is these
latter concentrations that determine in vivo insulin action in
each individual, however, and explain why insulin action is
delayed relative to changes in arterial insulin. Differences in
insulin action between lean and obese subjects are not due to
the rate of insulin delivery to the interstitium, but are determined by tissue factors, as demonstrated by the reduced coupling of glucose uptake and interstitial insulin.
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